Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Prolactin as an Adjunct for Type 1 Diabetes Immunotherapy.

Endocrinology | 2016

Type 1 diabetes is caused by autoimmune destruction of β-cells. Although immunotherapy can restore self-tolerance thereby halting continued immune-mediated β-cell loss, residual β-cell mass and function is often insufficient for normoglycemia. Using a growth factor to boost β-cell mass can potentially overcome this barrier and prolactin (PRL) may fill this role. Previous studies have shown that PRL can stimulate β-cell proliferation and up-regulate insulin synthesis and secretion while reducing lymphocytic infiltration of islets, suggesting that it may restore normoglycemia through complementary mechanisms. Here, we test the hypothesis that PRL can improve the efficacy of an immune modulator, the anticluster of differentiation 3 monoclonal antibody (aCD3), in inducing diabetes remission by up-regulating β-cell mass and function. Diabetic nonobese diabetic (NOD) mice were treated with a 5-day course of aCD3 with or without a concurrent 3-week course of PRL. We found that a higher proportion of diabetic mice treated with the aCD3 and PRL combined therapy achieved diabetes reversal than those treated with aCD3 alone. The aCD3 and PRL combined group had a higher β-cell proliferation rate, an increased β-cell fraction, larger islets, higher pancreatic insulin content, and greater glucose-stimulated insulin release. Lineage-tracing analysis found minimal contribution of β-cell neogenesis to the formation of new β-cells. Although we did not detect a significant difference in the number or proliferative capacity of T cells, we observed a higher proportion of insulitis-free islets in the aCD3 and PRL group. These results suggest that combining a growth factor with an immunotherapy may be an effective treatment paradigm for autoimmune diabetes.

Pubmed ID: 26512750 RIS Download

Mesh terms: Animals | Cell Enlargement | Cell Proliferation | Cells, Cultured | Combined Modality Therapy | Diabetes Mellitus, Type 1 | Drug Implants | Female | Hyperglycemia | Hypoglycemic Agents | Immunologic Factors | Insulin | Insulin Secretion | Insulin-Secreting Cells | Kaplan-Meier Estimate | Luminescent Proteins | Mice | Mice, Inbred NOD | Mice, Transgenic | Muromonab-CD3 | Prolactin | Recombinant Proteins | Remission Induction

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


RFP Antibody Pre-adsorbed (antibody)

RRID:AB_2209751

This polyclonal antibody targets RFP Pre-adsorbed

View all literature mentions

CD31 antibody (antibody)

RRID:AB_393571

This monoclonal antibody targets CD31

View all literature mentions

Insulin antibody (antibody)

RRID:AB_10013624

This polyclonal antibody targets Porcine pancreatic insulin

View all literature mentions

Anti-GLUT-2 antibody (antibody)

RRID:AB_1587076

This polyclonal antibody targets GLUT-2

View all literature mentions

BrdU antibody [BU1/75 (ICR1)] (antibody)

RRID:AB_305426

This monoclonal antibody targets BrdU antibody [BU1/75 (ICR1)]

View all literature mentions

Guinea Pig Anti-Glucagon IgG Fraction antibody (antibody)

RRID:AB_433707

This polyclonal antibody targets Guinea Pig Glucagon IgG Fraction

View all literature mentions